Abstract
Weight gain, diabetes, and changes in serum lipid profiles have been reported during treatment with typical and atypical antipsychotics. An association between diabetes and psychotic disorders was described long before the introduction of pharmacological agents for the treatment of schizophrenia. Several theories have been proposed to explain the baseline weight increase and metabolic disturbances in schizophrenia. Some studies suggest that increased food intake may improve psychotic symptoms in patients with schizophrenia but there have been conflicting results. Available clinical and basic research findings are discussed to evaluate the hypothesis that increased food intake may decrease sensitivity to dopamine signaling in the striatum. More research is needed to evaluate this potential link. However, basic animal research and evolutionary approaches can provide insights into metabolic disturbances associated with schizophrenia.
Keywords: Psychosis, Food Intake, Hypothesis, Weight gain, diabetes, pharmacological agents, schizophrenia, dopamine signaling
Current Molecular Pharmacology
Title: Can Increased Food Intake Improve Psychosis? A Brief Review and Hypothesis
Volume: 1
Author(s): T. Treuer, J. Karagianis and V. P. Hoffmann
Affiliation:
Keywords: Psychosis, Food Intake, Hypothesis, Weight gain, diabetes, pharmacological agents, schizophrenia, dopamine signaling
Abstract: Weight gain, diabetes, and changes in serum lipid profiles have been reported during treatment with typical and atypical antipsychotics. An association between diabetes and psychotic disorders was described long before the introduction of pharmacological agents for the treatment of schizophrenia. Several theories have been proposed to explain the baseline weight increase and metabolic disturbances in schizophrenia. Some studies suggest that increased food intake may improve psychotic symptoms in patients with schizophrenia but there have been conflicting results. Available clinical and basic research findings are discussed to evaluate the hypothesis that increased food intake may decrease sensitivity to dopamine signaling in the striatum. More research is needed to evaluate this potential link. However, basic animal research and evolutionary approaches can provide insights into metabolic disturbances associated with schizophrenia.
Export Options
About this article
Cite this article as:
Treuer T., Karagianis J. and Hoffmann P. V., Can Increased Food Intake Improve Psychosis? A Brief Review and Hypothesis, Current Molecular Pharmacology 2008; 1 (3) . https://dx.doi.org/10.2174/1874467210801030270
DOI https://dx.doi.org/10.2174/1874467210801030270 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Randomized Placebo-Controlled Trials of Omega-3 Polyunsaturated Fatty Acids in Psychiatric Disorders: A Review of the Current Literature
Current Drug Discovery Technologies New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function
Current Neuropharmacology <i>Withania somnifera</i> in Neurological Disorders: Ethnopharmacological Evidence, Mechanism of Action and its Progress in Delivery Systems
Current Drug Metabolism Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation Do mtDNA Mutations Participate in the Pathogenesis of Sporadic Parkinsons Disease?
Current Genomics Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism Molecular Recognisation of 3a, 4-Dihydro-3-H-Indeno [1, 2-C] Pyrazole-2- Carboxamide/Carbothioamide Anticonvulsant Analogues Towards GABA-Aminotransferase- An in Silico Approach
Central Nervous System Agents in Medicinal Chemistry Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Botulinum Toxin: Pharmacology and Clinical Developments: A Literature Review
Medicinal Chemistry Conditioned Avoidance Response in the Development of New Antipsychotics
Current Pharmaceutical Design The Importance of Melatonin and Mitochondria Interaction in Mood Disorders and Schizophrenia: A Current Assessment
Current Medicinal Chemistry Unmet Needs in Schizophrenia
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Computer-aided Drug Design Applied to Parkinson Targets
Current Neuropharmacology Nanomedicine against Alzheimer’s and Parkinson’s Disease
Current Pharmaceutical Design The Role of Topiramate in the Management of Cocaine Addiction: a Possible Therapeutic Option
Current Neuropharmacology Dual Ligands Targeting Dopamine D2 and Serotonin 5-HT<sub>1A</sub> Receptors as New Antipsychotical or Anti-Parkinsonian Agents
Current Medicinal Chemistry Neural Basis of Dental Pulp Stem Cells and its Potential Application in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Stem Cell Therapy for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Advances in Clinical Study of Curcumin
Current Pharmaceutical Design